PHASE III RANDOMIZED TRIAL OF VOLASERTIB PLUS LOW-DOSE CYTARABINE (LDAC) VERSUS PLACEBO PLUS LDAC IN PATIENTS AGED >= 65 YEARS WITH PREVIOUSLY UNTREATED AML, INELIGIBLE FOR INTENSIVE THERAPYH. Dohner,A. Symeonidis,M. A. Sanz, D. Deeren,J. Demeter,A. Anagnostopoulos,J. Esteve,W. Fiedler,K. Porkka, H. J. Kim, J. H. Lee, K. Usuki, C. W. Jung, S. D'Ardia,O. Salamero,H. A. Horst, C. Recher, P. Rousselot,I. Sandhu, K. Theunissen,F. Thol,K. Dohner,V. Teleanu,D. J. DeAngelo,T. Naoe,M. A. Sekeres, V. Belsack, M. Ge,T. Taube,O. G. OttmannHAEMATOLOGICA（2016）引用 0|浏览5暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
